Related references
Note: Only part of the references are listed.BET Proteins as Targets for Anticancer Treatment
Anastasios Stathis et al.
CANCER DISCOVERY (2018)
Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns
Laura Magill Sack et al.
CELL (2018)
The Expanding World of N-MYC-Driven Tumors
David S. Rickman et al.
CANCER DISCOVERY (2018)
AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells
Ji Eun Jang et al.
CLINICAL CANCER RESEARCH (2017)
A genetic interaction analysis identifies cancer drivers that modify EGFR dependency
Sida Liao et al.
GENES & DEVELOPMENT (2017)
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
Hana Janouskova et al.
NATURE MEDICINE (2017)
DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer
Riikka J. Lund et al.
SCIENTIFIC REPORTS (2017)
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance
Richard Marcotte et al.
CELL (2016)
RB1: a prototype tumor suppressor and an enigma
Nicholas J. Dyson
GENES & DEVELOPMENT (2016)
CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer
Mark L. McCleland et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members
Simon J. Hogg et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shaokun Shu et al.
NATURE (2016)
Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown
Mihaela Pertea et al.
NATURE PROTOCOLS (2016)
Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms
Xiarong Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
Anastasios Stathis et al.
CANCER DISCOVERY (2016)
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
Alison M. Kurimchak et al.
Cell Reports (2016)
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma
Filemon S. Dela Cruz et al.
GENOME MEDICINE (2016)
The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains
Artyom A. Alekseyenko et al.
GENES & DEVELOPMENT (2015)
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
John C. Hunter et al.
MOLECULAR CANCER RESEARCH (2015)
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong et al.
NATURE (2015)
Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer
M. K. Farrugia et al.
CELL DEATH & DISEASE (2015)
GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
Krishan Kumar et al.
Scientific Reports (2015)
Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
Matteo S. Carlino et al.
CLINICAL CANCER RESEARCH (2015)
Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus
Jian-Feng Xiang et al.
CELL RESEARCH (2014)
Comparison of the Effects of PRKAR1A and PRKAR2B Depletion on Signaling Pathways, Cell Growth, and Cell Cycle Control of Adrenocortical Cells
F. Basso et al.
HORMONE AND METABOLIC RESEARCH (2014)
GNAS mutation as an alternative mechanism of activation of the Wnt/beta-catenin signaling pathway in gastric adenocarcinoma of the fundic gland type
Ryosuke Nomura et al.
HUMAN PATHOLOGY (2014)
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
Thomas De Raedt et al.
NATURE (2014)
Improved vectors and genome-wide libraries for CRISPR screening
Neville E. Sanjana et al.
NATURE METHODS (2014)
MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma
A. R. Grayson et al.
ONCOGENE (2014)
Genetic modifiers of EGFR dependence in non-small cell lung cancer
Tanaz Sharifnia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
Wei Li et al.
GENOME BIOLOGY (2014)
Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome
Teresa Davoli et al.
CELL (2013)
The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote
Yang Liao et al.
NUCLEIC ACIDS RESEARCH (2013)
A role for PVRL4-driven cell-cell interactions in tumorigenesis
Natalya N. Pavlova et al.
ELIFE (2013)
A Molecular Roadmap of Reprogramming Somatic Cells into iPS Cells
Jose M. Polo et al.
CELL (2012)
Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma
Daniel E. Bauer et al.
CLINICAL CANCER RESEARCH (2012)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Roland Schmitz et al.
NATURE (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth
Fred Harbinski et al.
CANCER DISCOVERY (2012)
Switching TGFβ from a tumor suppressor to a tumor promoter
Gareth J. Inman
CURRENT OPINION IN GENETICS & DEVELOPMENT (2011)
Wnt/β-catenin signaling is differentially regulated by Gα proteins and contributes to fibrous dysplasia
Jean B. Regard et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
Mark D. Robinson et al.
BIOINFORMATICS (2010)
Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling
Madson Q. Almeida et al.
HUMAN MOLECULAR GENETICS (2010)
Mutations and Polymorphisms in the Gene Encoding Regulatory Subunit Type 1-Alpha of Protein Kinase A (PRKAR1A): An Update
Anelia Horvath et al.
HUMAN MUTATION (2010)
The activating mutation R201C in GNAS promotes intestinal tumourigenesis in ApcMin/+ mice through activation of Wnt and ERK1/2 MAPK pathways
C. H. Wilson et al.
ONCOGENE (2010)
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes
Joseph H. Taube et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
EPIGENETICS AND GENETICS A census of amplified and overexpressed human cancer genes
Thomas Santarius et al.
NATURE REVIEWS CANCER (2010)
Mutations in Regulatory Subunit Type 1A of Cyclic Adenosine 5′-Monophosphate-Dependent Protein Kinase (PRKAR1A): Phenotype Analysis in 353 Patients and 80 Different Genotypes
Jerome Bertherat et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
An immortalized human cell line bearing a PRKAR1A-inactivating mutation:: Effects of overexpression of the wild-type allele and other protein kinase A subunits
Maria Nesterova et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells
C. A. French et al.
ONCOGENE (2008)
PRKAR1A inactivation leads to increased proliferation and decreased apoptosis in human B lymphocytes
Audrey J. Robinson-White et al.
CANCER RESEARCH (2006)
PRKAR1A mutations and protein kinase A interactions with other signaling pathways in the adrenal cortex
Audrey Robinson-White et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai et al.
NATURE PROTOCOLS (2006)
KLF4, p21 and context-dependent opposing forces in cancer
BD Rowland et al.
NATURE REVIEWS CANCER (2006)
Disruption of protein kinase A regulation causes immortalization and dysregulation of D-type cyclins
KS Nadella et al.
CANCER RESEARCH (2005)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation
M Welcker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7
M Yada et al.
EMBO JOURNAL (2004)
Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2
A Robinson-White et al.
HUMAN MOLECULAR GENETICS (2003)
Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients
JA Toretsky et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2003)
Involvement of phosphatidylinositol 3-kinase, but not RalGDS, in TC21/R-Ras2-mediated transformation
GA Murphy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase
DM Koepp et al.
SCIENCE (2001)
Activation of the Ral and phosphatidylinositol 3′ kinase signaling pathways by the ras-related protein TC21
M Rosário et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Regulatory proteins of R-Ras, TC21/R-Ras2, and M-Ras/R-Ras3
Y Ohba et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
